Wyroba Jakub, Kochan Joanna
Malopolski Institute of Fertility Diagnostics and Treatment - krakOvi, Krakow, Poland.
Fertility Disorders Clinic, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.
JBRA Assist Reprod. 2025 Feb 21;29(2):298-305. doi: 10.5935/1518-0557.20240111.
The aim of the study was to analyze the effectiveness of the day 3 ET strategy, and the morphology of the transferred embryos, in patients from POSEIDON and non-POSEIDON groups.
600 cycles of patients meeting the POSEIDON criteria and 600 non-POSEIDON cycles were analyzed to determine the proportion of cycles with an ET on days 3 or 5, or FET. Then we reviewed 330 day 3 ETs to compared the developmental stage, morphology, zona pellucida thickness and implantation potential of embryos transferred on day 3 from POSEIDON and non-POSEIDON patients.
Most cycles of POSEIDON patients end with ET on day 3 (42%) or without transfer (37%). In contrast, most cycle of non-POSEIDON patients end with FET (44%) and just 9% is canceled. The lowest percentage of embryos at the morula stage was recorded in POSEIDON groups III (10%) and IV (9%). The average number of cells in embryos was comparable in all groups. The largest percentage of top-quality embryos (grade A) were in POSEIDON group I (47%) .The highest implantation potential were observed in the non-POSEIDON group <35Y (28%), and in POSEIDON groups I (28%) and III (26%). The highest incidence of miscarriage was recorded in all POSEIDON and non-POSEIDON groups that included patients who were ≥35 years of age.
The day 3 ET strategy still seems optimal for POSEIDON patients. The prognosis depends on which Poseidon group the patient is in. The best prognosis is for group I and the worst for group IV.
本研究旨在分析在波塞冬组和非波塞冬组患者中,第3天胚胎移植(ET)策略的有效性以及移植胚胎的形态。
分析600个符合波塞冬标准患者的周期以及600个非波塞冬周期,以确定在第3天或第5天进行ET或冻融胚胎移植(FET)的周期比例。然后,我们回顾了330例第3天ET,比较了波塞冬组和非波塞冬组患者在第3天移植胚胎的发育阶段、形态、透明带厚度和着床潜力。
波塞冬组患者的大多数周期在第3天进行ET结束(42%)或未进行移植(37%)。相比之下,非波塞冬组患者的大多数周期以FET结束(44%),仅有9%被取消。在波塞冬组III(10%)和IV(9%)中,桑椹胚阶段的胚胎百分比最低。所有组中胚胎的平均细胞数相当。优质胚胎(A级)比例最高的是波塞冬组I(47%)。在非波塞冬组<35岁患者中(28%)以及波塞冬组I(28%)和III(26%)中观察到最高的着床潜力。在所有包括≥35岁患者的波塞冬组和非波塞冬组中,流产发生率最高。
对于波塞冬组患者,第3天ET策略似乎仍然是最佳选择。预后取决于患者所属的波塞冬组。I组预后最佳,IV组最差。